Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 Akedo Akedo +48.65%
#3 DOVU DOVU +48.14%
#4 Velvet Velvet +43.34%
#5 Black Phoenix Black Phoenix +33.95%
#6 Cross Cross +24.30%
#7 Cap Cap +20.40%
#8 DoubleZero DoubleZero +15.97%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.98%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +9.29%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Oxurion N.V. Oxurion N.V.

Oxurion N.V.

OXUR
Kedudukan dalam Saham #39565
Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a... Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized offering is JETREA, a medication used to address vitreomacular adhesion and vitreomacular traction. The company's development pipeline includes THR-149, a plasma kallikrein inhibitor currently undergoing Phase II clinical trials for diabetic macular edema (DME), and THR-687, an integrin antagonist also in Phase II trials for DME. Oxurion has forged strategic partnerships with Bicycle Therapeutics, INC Research, and Galapagos NV. The organization was formerly known as ThromboGenics NV before officially changing its name to Oxurion NV in September 2018.
Harga Saham
$0.003084
Modal Pasaran
$434.03K
Perubahan (1 hari)
-7.14%
Perubahan (1 tahun)
-89.24%
Negara
BE
Perdagangan Oxurion N.V. (OXUR)

Kategori

Healthcare
Pendapatan untuk Oxurion N.V. (OXUR)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Oxurion N.V., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Oxurion N.V. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE